Lannett Co (Lannett Co) Momentum Rank : 0 (As of May. 04, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Momentum Rank?

Lannett Co has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Lannett Co Momentum Rank Related Terms

Thank you for viewing the detailed overview of Lannett Co's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lannett Co (Lannett Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053

Website

https://www.lannett.com

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.

Executives

John C Chapman	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew	officer: Chief Executive Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber	officer: Secretary
Samuel H Israel	officer: Chief Legal Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt	officer: Vice President of Quality	9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski	officer: Chief Operating Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik	director	9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa	director	9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith	other: Vice President
Maureen Cavanaugh	officer: Senior Vice President and CCOO	9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber	officer: Treasurer
Arthur P Bedrosian	officer: President	P O BOX D 1400, POMONA NY 10970